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Summary Prostaglandins E2 and F2Q (PGE2 and PGF2-) were measured by Gas Liquid Chromatography -
Mass Spectrometry (GLC-MS) in extracts of 100 human mammary carcinomas. All tumours contained
measurable amounts of both prostaglandins but wide variations between individual tumours were observed.
Values for PGE2 ranged from 7 to 762ngg-' tissue with a median of lOOngg-' tissue. Values for PGF2Q
ranged from 3 to 475ngg-' tissue (median 60ngg-' tissue). There was a highly significant positive
correlation between amounts of the 2 prostaglandins in individual tumours. Amounts of both PGE2 and
PGF2, were not significantly related to the menopausal status of the patients or the presence of oestrogen and
progesterone receptors.
Human mammary cancers appear to produce
prostaglandin-like material, and this may be
involved in tumour growth and metastases (Bennet
et al., 1977; Rolland et al., 1980). Most
investigations have, however, employed bioassay or
radioimmunoassay techniques which do not
definitively identify prostaglandins. A single study
has reported on determinations performed by GLC-
mass spectrometry but the number of tumours
examined was relatively small (Stamford, 1983).
The present investigation represents a study of 100
human mammary cancers in which PGE2 and
PGF2. have been identified and quantitated by
GLC-mass spectrometry. Values of prostaglandins
have then been related to tumour steroid receptor
status.
Materials and methods
Tumours
Tumour was obtained from 100 women with
carcinoma of the breast. These patients comprised
15 premenopausal, 10 perimenopausal (within 5
years of the last menstrual period) and 75 post
menopausal women. Tumour was removed at
mastectomy or biopsy from the primary cancer (in
88 women), by biopsy of invaded lymph node (in 9
cases) or secondary recurrences (in 3 cases). For
comparative purposes, material was also obtained
from benign fibroadenoma of the breast in 5
women and from histologically normal breast tissue
in 3 women. This material was placed on ice and
immediately transferred to the laboratory.
Following removal of tissue for histopathological
diagnosis, the remaining material was dissected free
of extraneous fat and divided for prostaglandin and
steroid receptor assays.
Measurement ofprostaglandins
Formation of derivatives Tumour samples were
weighed and homogenized inethanol (2.5ml). To 1 ml
duplicates of each sample were added 20ng of the
internal standards, (20-ethyl PGF2. and 20-methyl
PGE2.). Oximes were formed by adding
hydroxylaminehydrochloride solution (50mgml-1)
in sodium acetate buffer (3mol P1, pH 5.2) and
heating for 30min at 60°C. The samples were
extracted and purified using a C18 Seppak column,
washed with 10ml iso-octane and then 10ml 50%
methanol to remove neutral lipids. The
prostaglandins were then eluted with 90% methanol
(10ml). This fraction was evaporated to dryness
and the residue dissolved in ethyl acetate:ethanol
(1:lv/v), transferred to a small flat-bottomed tube
and methylated with 100p1 diazomethane solution.
Excess diazomethane and solvent were then
evaporated. The residue was further derivatized to
the t-butyldimethylsilyl ether by adding 65pl 2M-
butyldimethylchlorosilane and 65pl 4M-imidazole
(both in dimethylformamide). After mixing, this
solution was transferred to a narrow glass tube
which was then sealed and heated for 30min at
130°C. The excess reagents were removed from this
mixture by eluting the derivative with 3ml
hexane:ethylacetate (3:1v/v) from a Sephadex LH-
20 column. The solvent was evaporated and 20.u1
toluene added to the derivative. About one
twentieth of this mixture was injected into the gas
chromatograph.
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Gas chromatography - mass spectrometry
Samples were analysed with a Erba Science gas
chromatograph coupled through an all-glass jet
separator to a V.G.305 mass spectrometer. An open
tubular column coated with SE30 and 12 m long
(SGE Ltd. London) was used. The flow rate of
helium was 5mlmin-1. The temperatures were
maintained as follows: gas-chromatography column
280°C; separator and lines 260°C; source block
270°C. The signal was processed by a 2150 data
system to allow separate GC traces for each.
For analysis of PGF2. the mass used was m/z
653 and 681 and for PGE2, m/z 666 and 680. The
ions measured were the M-57 ions resulting from
the loss of a t-butyl radical from the molecular ion.
Quantitation was achieved by comparing the areas
of the sample peak with those of the corresponding
standards. Procedural losses were corrected by
monitoring the recovery of the internal standards,
20 methyl PGE2 (m/z 680) and 20 ethyl PGF2.
(m/z 681). The intra-assay precision was 13%;
values for interassay precision were 18 and 21% for
PGF2, and PGE2 respectively.
Oestrogen receptors
Concentration of oestrogen receptors was
determined by saturation analysis (Hawkins et al.,
1975). Tumour cytosol was incubated overnight at
4°C with [3H] 17 P-oestradiol. Separation offree and
bound steroid was by addition of dextran-coated
charcoal; the bound fraction was measured by
liquid scintillation counting. Concentration of
receptors was determined by Scatchard analysis
(Scatchard, 1949). Activities in excess of
5fmolmg-1 cytosol protein were designated
receptor positive.
Progestogen receptors
Cytosol was incubated with a fixed concentration
of [3H] Organon-2058 (0.22nM) and varying
concentrations of non-radioactive Organon-2058
(0.22-l1.1 nM) with overnight binding at 0°C and
separation of free and bound hormone by charcoal
adsorption (Hawkins et al., 1981). Activities in
excess of 10fmolmg-1 cytosol protein were
designated receptor positive.
Protein concentration in the cytosol was
determined by the method of Bradford (1976).
Statistical analysis
Non-parametric tests (i.e. Wilcoxon's Rank Test
and Spearman's Rank correlation) were used
throughout these studies.
Results
Measurable amounts of PGE2 and PGF2. were
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Figure 1 Levels of PGE2 and PGF2. in 100 human
breast cancers. Lines represent the median values.
detected in all carcinomas. Levels in individual
tumours are shown in Figure 1. Range of values for
PGE2 was from 7 to 762ngg-1 tissue with a
median value of 100. The corresponding range for
PGF2. in the same samples was from 3 to
475ngg-1 tissue (median 60). Values in a group of
5 fibroadenomas ranged from 2-19ngg-1 tissue
(median 9) for PGE2 and 6-14ngg-1 tissue
(median 12) for PGF2. and those for 3 specimens
of histologically normal breast were 7-14ngg-
tissue for PGE2 and 5-18ngg-1 for PGF2a.
Within the group of breast cancers, there was a
highly significant correlation between amounts of
PGE2 and PGF2. (Figure 2). (Spearman's Rank
correlation coefficient =0.543 P<0.001).
There was no significant difference between
prostaglandin levels in primary tumours, lymph
nodes and secondary recurrences (Data not shown).
Nor were there significant differences in amounts of
either PGE2 or PGF2. in pre, peri and
postmenopausal patients (Figure 3).
Oestrogen receptor activity was detected in 68
tumours (68%) and the relationship between the
presence of receptors and prostaglandin content isPROSTAGLANDINS IN HUMAN MAMMARY CANCER
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Figure 2 The relationship between levels of PGE2
and PGF20. Line is that of linear correlation.
Correlation coefficient by Spearman Rank test 0.543
P<0.00l.
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Figure 3 Levels of prostaglandins in tumours from
pre, peri and postmenopausal patients. Lines represent
median values. No significant differences between the
groups by Wilcoxon Rank Test.
shown in Figure 4. The median value for both
PGE2 and PGF2. was higher in tumours with
oestrogen receptors as compared to those without
receptors, but the difference between the two
+
Oestrogen receptor
Figure 4 Levels of prostaglandins in oestrogen
receptor positive (+) and negative (-) tumours. Lines
represent median values. No significant difference
between the groups by Wilcoxon Rank Test.
groups failed to reach statistical significance.
(P<0.1 and P<0.2, respectively by Wilcoxon Rank
Sum Test).
Progesterone receptors were detected in 34 of the
93 tumours investigated (37%). There was no
significant difference between either PGE2 or
PGF2. levels in progesterone receptor positive and
negative tumours (Figure 5). (P<0.8 and P<0.9
respectively by Wilcoxon Rank Sum Test).
Discussion
To date, the evidence that human breast cancers
contain significant amounts of prostaglandins has
been based on data from either bioassay or
radioimmunoassay. These techniques, although of
value, do not accurately identify different
prostaglandins. In the present study, therefore, we
have used the more definitive technique of GLC-
mass spectrometry which has previously only been
employed for prostaglandin measurements in a
small group of breast cancers (Stamford, 1983).
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Figure 5 Levels of prostaglandins in progesterone
receptor positive (+) and negative (-) tumours. Lines
represent median values. No significant difference
between the groups by Wilcoxon Rank Test.
It is almost impossible to measure "in situ" levels
of prostaglandins within tissue preparations
because prostaglandins are not stored in cells but
are synthesised rapidly in response to stimuli.
Biopsy, processing and homogenization of tumour
specimens represent stimuli which would result in
production of large amounts of prostaglandins.
Determination of prostaglandins in tumours can,
therefore, only be directed towards assessing the
potential for prostaglandin production rather than
measurement of endogenous levels (Green, 1979).
Two types of technique have been adopted in this
respect. Tumour may be homogenized directly in
ethanol to obtain "basal" levels or incubated with
or without added precursor to determine
"synthesised" levels. It is not clear which technique
more accurately reflects tumour potential for
producing a local environment of prostaglandins or
indeed if either reflects "in situ" activity. "Basal"
levels will include both the normal content of
tumour cells and material synthesized between
biopsy and inactivation of synthetic ensymes during
homogenisation (Bennet, 1982). The level of
prostaglandin 'synthesized" will depend critically on
precautions taken to protect the highly labile
prostaglandin synthetase system and addition of
arachidonate substrate may not mimic tissue levels
of precursor. We have, therefore, chosen to
measure basal levels of prostaglandins in the
present study because this represents the least
complicated and most practical method of studying
prostaglandins in a large number of cancers.
Using these techniques, measurable amounts of
PGE2 and PGF2. were detected in all tumours.
Prostaglandins were identified on the basis of their
molecular ions (at m/z 666 PGE2, m/z 653 for
PGF2a), retention times and characteristic peaks.
Amounts of PGE2 varied from 7 to 762ngg-1
tissue and those of PGF2. from 3 to 475ngg-1
tissue. These amounts are comparable to
concentrations demonstrated by other methods
(Bennet, 1982) and were higher than those found in
benign and normal breast. A strong positive
correlation was detected between levels of the two
prostaglandins in individual breast cancers as has
been previously observed (Fulton et al., 1982).
Although the variation in the amounts of both
prostaglandins was large, we have been unable to
identify factors accounting for this variation. Levels
of tumour prostaglandins appeared to be
uninfluenced by menopausal status of the patient,
site of tumour biopsy or whether cytosolic steroid
receptors were present.
The finding of no significant difference in tumour
prostaglandin levels between pre, peri and post-
menopausal patients agrees with the results of
Rolland et al. (1980) who measured "synthesized"
levels of prostaglandins in microsomal preparations.
Fulton et al. (1982) failed to show an association
with PGF2. but reported significantly raised PGE2
levels in postmenopausal women. It has been
suggested that oestrogen receptor positive tumours
synthesize greater amounts of prostaglandins
(Campbell et al., 1982). Others have been unable to
show such a correlation (Rolland et al., 1980;
Bennet, 1982). However, in the study which
reported a significant correlation, it was necessary
to make a correction for tumour cellularity before
the association became apparent. In the present
study, a significant correlation was apparent
between tumour cellularity and PGE2 but not
PGF2a (Figure 6). However, multiple regression
analysis of PGE2 and PGF2. on both oestrogen
receptor and cellularity showed that oestrogen
receptor had no significant effect on prostaglandins
for given levels of cellularity (for PGE2 t=0.36, for
PGF2,t=1.12). Indeed, correcting the results for
tumour cellularity may be misleading because this
would be based on the assumption that tumour
cells within the biopsy were solely responsiblePROSTAGLANDINS IN HUMAN MAMMARY CANCER 463
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Figure 6 Levels of prostaglandins in tumours with
different grades of cellularity. Cellularity was assessed
as described by Hawkins et al. (1981) using a 4 point
scale for both the proportion of tumour in the tissue
specimen and for the proportion of malignant cells
within the tumour itself. These are expressed as a
product of the two scores to give a range of 1-16.
(Score 1-4 therefore represents tumours with a low
cellularity index, those with 13-16 the highest) PGE2
correlates signifilcantly with cellularity (t=O 014,
P<O0.05, by Kendal Rank Test). PGF2< did not
correlate significantly with cellularity (t=0.08).
whereas other cell types such as macrophages,
lymphocyctes, plasma cells and fibroblasts may also
be producing prostaglandins. We have, therefore,
preferred to express our results in terms of
prostaglandins extracted per weight of tumour
tissue.
Variation in prostaglandins extractable from
breast cancers may be due to non-specific, non-
tumour factors such as the time interval between
the biopsy and extraction, and the degree of trauma
produced in obtaining the tumour samples.
Enzymes associated with prostaglandin synthesis
are particularly labile (Egan et al., 1978) and it is
essential to minimise any delay in tumour
processing. Substantial amounts of prostaglandins
may be generated in response to trauma (Green,
1979) and variation in degree of tissue trauma
might be expected to be associated with differences
in prostaglandins levels. In practice, it is difficult to
eliminate tissue trauma as even gentle handling may
stimulate biosynthesis of prostaglandins. In this
series of tumours, clinical and pathological
considerations determined the degree of mechanical
trauma to which the specimens were subjected.
However, no significant differences were detected
between prostaglandins extracted from samples
obtained at biopsy and those from mastectomy
specimens.
It has been suggested that tumour prostaglandins
are associated with prognosis and pattern of
metastatic spread of breast cancer. At the present
time, data from this study cannot be assessed for
these parameters. Most tumours were obtained
from patients with early breast cancer who have, as
yet, only short follow-up. The absence of positive
correlations with other factors of known prognostic
value such as steroid receptors and lymph node
status could mean that prostaglandins are either of
independent significance or unrelated to prognosis.
Valid assessment of the data will only be possible
when further follow-up of the patients is available.
We would like to thank Professor A.P.M. Forrest for
allowing us to study material from patients under his care,
Dr J.M.J. Dixon for assessing the cellularity of each
tumour and Dr R.A. Elton, Department of Medical
Statistics and Computing for statistical analysis of the
results.
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